The psychopharmacological management of eating disorders in children and adolescents

References

• Aigner M, Treasure J, Kaye W, Kasper S. 2011. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World Journal of Biological Psychiatry 12: 400–443.
   PubMed Web of Science ®Google Scholar
• APA (American Psychiatric Association). 2000. Diagnostic and statistical manual of mental disorders: DSM-IV-TR^®. Arlington, Virginia: American Psychiatric Publishing.
   Google Scholar
• APA (American Psychiatric Association). 2006. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: compendium 2006. Arlington, Virginia: American Psychiatric Publishing.
   Google Scholar
• APA (American Psychiatric Association). 2013. Diagnostic and statistical manual of mental disorders (5th edn). Arlington, Virginia: American Psychiatric Publishing.
   Google Scholar
• Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W. 2003. A randomised, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Archives of General Psychiatry 60: 1109.
   PubMed Web of Science ®Google Scholar
• Attia E, Haiman C, Walsh BT, Flater SR. 1998. Does fluoxetine augment the inpatient treatment of anorexia nervosa?. American Journal of Psychiatry 155: 548–551.
   PubMed Web of Science ®Google Scholar
• Attia E, Mayer L, Killroy E. 2001. Medication response in the treatment of patients with anorexia nervosa. Journal of Psychiatric Practice 7: 157–162.
   PubMedGoogle Scholar
• Bacaltchuk J, Hay P. 2003. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Systematic Reviews 4: CD003391.
   PubMedGoogle Scholar
• Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. 2003. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomised controlled trial. Journal of the American Medical Association 289: 1805–1812.
   PubMed Web of Science ®Google Scholar
• Birmingham CL, Goldner EM, Bakan R. 1994. Controlled trial of zinc supplementation in anorexia nervosa. International Journal of Eating Disorders 15: 251–255.
   PubMed Web of Science ®Google Scholar
• Bishop-Gilyard CT, Berkowitz RI, Wadden TA, Gehrman CA, Cronquist JL, Moore RH. 2011. Weight reduction in obese adolescents with and without binge eating. Obesity 19: 982–987.
   PubMed Web of Science ®Google Scholar
• Boachie A, Goldfield GS, Spettigue W. 2003. Olanzapine use as an adjunctive treatment for hospitalised children with anorexia nervosa: case reports. International Journal of Eating Disorders 33: 98–103.
   PubMed Web of Science ®Google Scholar
• Brennan BP, Roberts JL, Fogarty KV, Reynolds KA, Jonas JM, Hudson JI. 2008. Memantine in the treatment of binge eating disorder: An open-label, prospective trial. International Journal of Eating Disorders 41: 520–526.
   PubMed Web of Science ®Google Scholar
• Brewerton TD. 1995. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 20: 561–590.
   PubMed Web of Science ®Google Scholar
• Brewerton TD. 2012. Antipsychotic agents in the treatment of anorexia nervosa: neuropsychopharmacologic rationale and evidence from controlled trials. Current Psychiatry Reports 14: 398–405.
   PubMedGoogle Scholar
• Brownley KA, Berkman ND, Sedway JA, Lohr KN, Bulik CM. 2007. Binge eating disorder treatment: a systematic review of randomised controlled trials. International Journal of Eating Disorders 40: 337–348.
   PubMed Web of Science ®Google Scholar
• Bulik CM, Berkman ND, Brownley KA, Sedway JA, Lohr KN. 2007. Anorexia nervosa treatment: A systematic review of randomised controlled trials. International Journal of Eating Disorders 40: 310–320.
   PubMed Web of Science ®Google Scholar
• Chan JL, Mantzoros CS. 2005. Role of leptin in energy-deprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. The Lancet 366: 74–85.
   PubMed Web of Science ®Google Scholar
• Claudino A, Hay P, Lima M, Bacaltchuk J, Schmidt U, Treasure J. 2006. Antidepressants for anorexia nervosa. Cochrane Database Systematic Reviews 1: CD004365.
   Google Scholar
• Colton P, Woodside DB, Kaplan AS. 1999. Laxative withdrawal in eating disorders: Treatment protocol and 3 to 20-month follow-up. International Journal of Eating Disorders 25: 311–317.
   PubMedGoogle Scholar
• Couturier J, Lock J. 2007. A review of medication use for children and adolescents with eating disorders. Journal of the Canadian Academy of Child and Adolescent Psychiatry 16: 173–176.
   PubMedGoogle Scholar
• Crow SJ, Mitchell JE, Roerig JD, Steffen K. 2009. What potential role is there for medication treatment in anorexia nervosa?. International Journal of Eating Disorders 42: 1–8.
   PubMed Web of Science ®Google Scholar
• Currin L, Schmidt U, Treasure J, Jick H. 2005. Time trends in eating disorder incidence. The British Journal of Psychiatry 186: 132–135.
   PubMed Web of Science ®Google Scholar
• Díaz EG, Folgueras TM. 2011. Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents. Nutrición hospitalaria 26: 451–457.
   PubMed Web of Science ®Google Scholar
• Dennis K, Le Grange D, Bremer J. 2006. Olanzapine use in adolescent anorexia nervosa. Eating and weight disorders 11: 53–56.
   Google Scholar
• Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. 2007. Cognitive behavioral therapy and fluoxetine for binge eating disorder: Two-year follow-up. Obesity 15: 1702–1709.
   PubMed Web of Science ®Google Scholar
• Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED. 2000. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. The Lancet 355: 792–797.
   PubMed Web of Science ®Google Scholar
• Favaro A, Caregaro L, Tenconi E, Bosello R, Santonastaso P. 2009. Time trends in age at onset of anorexia nervosa and bulimia nervosa. The Journal of Clinical Psychiatry 70: 1715–1721.
   PubMed Web of Science ®Google Scholar
• Field AE, Javaras KM, Aneja P, Kitos N, Camargo CA Jr, Taylor CB, Laird NM. 2008. Family, peer, and media predictors of becoming eating disordered. Archives of Pediatrics & Adolescent Medicine 162: 574–579.
   PubMed Web of Science ®Google Scholar
• Flament MF, Bissada H, Spettigue W. 2012. Evidence-based pharmacotherapy of eating disorders. International Journal of Neuro-Psychopharmacology 15: 189–207.
   PubMed Web of Science ®Google Scholar
• Gauthier C, Hassler C, Mattar L, Launay J, Callebert J, Steiger H, Melchior J, Falissard B, Berthoz S, Mourier-Soleillant V. 2014. Symptoms of depression and anxiety in anorexia nervosa: Links with plasma tryptophan and serotonin metabolism. Psychoneuroendocrinology 39: 170–178.
   PubMed Web of Science ®Google Scholar
• Gregorowski C, Seedat S, Jordaan GP. 2013. A clinical approach to the assessment and management of co-morbid eating disorders and substance use disorders. BMC Psychiatry 13: 289.
   PubMed Web of Science ®Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, Gachoud J, Chabloz M, Kammer A, Schutz Y. 2005. Effect of orlistat in obese patients with binge eating disorder. Obesity Research 13: 1701–1708.
   PubMedGoogle Scholar
• Golden NH, Attia E. 2011. Psychopharmacology of eating disorders in children and adolescents. Pediatric Clinics of North America 58: 121–138.
   PubMed Web of Science ®Google Scholar
• Gowers S, Claxton M, Rowlands L, Inbasagaran A, Wood D, Yi I, Hugo P, Clark-Stone S, Bryant-Waugh R, Nicholls D. 2010. Drug prescribing in child and adolescent eating disorder services. Child and Adolescent Mental Health 15: 18–22.
   Google Scholar
• Grilo CM, Masheb RM, Salant SL. 2005. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomised, double-blind, placebo-controlled trial. Biological Psychiatry 57: 1193–1201.
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Welge JA, Nelson E, Keck PE, Hudson JI. 2009. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomised, placebo-controlled monotherapy trial. International Clinical Psychopharmacology 24: 150–158.
   PubMed Web of Science ®Google Scholar
• Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, O'Lonergan T, Frank G, Wamboldt MZ. 2011. A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. Journal of the American Academy of Child & Adolescent Psychiatry 50: 915–924.
   PubMed Web of Science ®Google Scholar
• Hay P, Claudino A, Kaio M. 2001. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Systematic Reviews 4: D003385.
   Google Scholar
• Hebebrand J, Albayrak Ö. 2012. Leptin treatment of patients with anorexia nervosa? The urgent need for initiation of clinical studies. European Child & Adolescent Psychiatry 21: 63–66.
   PubMed Web of Science ®Google Scholar
• Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, Capece JA. 2003. Treatment of bulimia nervosa with topiramate in a randomised, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. The Journal of Clinical Psychiatry 64: 1449–1454.
   PubMed Web of Science ®Google Scholar
• Holtkamp K, Konrad K, Kaiser N, Ploenes Y, Heussen N, Grzella I, Herpertz-Dahlmann B. 2005. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. Journal of Psychiatric Research 39: 303–310.
   PubMed Web of Science ®Google Scholar
• Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, Capece JA, Karvois D. 2003. Treatment of bulimia nervosa with topiramate in a randomised, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. The Journal of Clinical Psychiatry 64: 1335–1341.
   PubMed Web of Science ®Google Scholar
• Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH. 2011. A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. Journal of Child and Adolescent Psychopharmacology 21: 207–212.
   PubMed Web of Science ®Google Scholar
• Kanekar A, Sharma M. 2010. Pharmacological approaches for management of child and adolescent obesity. Journal of Clinical Medicine Research 2: 105–111.
   PubMedGoogle Scholar
• Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM, Glader LJ. 1987. Zinc deficiency in anorexia nervosa. Journal of Adolescent Health Care 8: 400–406.
   PubMedGoogle Scholar
• Kaye W. 2008. Neurobiology of anorexia and bulimia nervosa. Physiology & Behavior 94: 121–135.
   PubMed Web of Science ®Google Scholar
• Kaye WH, Nagata T, Weltzin TE, Hsu L, Sokol MS, McConaha C, Plotnicov KH, Weise J, Deep D. 2001. Double-blind placebo-controlled administration of fluoxetine in restricting-and restricting-purging-type anorexia nervosa. Biological Psychiatry 49: 644–652.
   PubMed Web of Science ®Google Scholar
• Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. 2012. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. The Journal of Clinical Psychiatry 73: 757–766.
   PubMedGoogle Scholar
• Klibanski A, Lawson EA. 2008. Endocrine abnormalities in anorexia nervosa. Nature Clinical Practice Endocrinology & Metabolism 4: 407–414.
   PubMedGoogle Scholar
• Kotler L. 2000. Eating disorders in children and adolescents: pharmacological therapies. European Child & Adolescent Psychiatry 9: S108–S116.
   Google Scholar
• Kotler LA, Devlin MJ, Davies M, Walsh BT. 2003. An open trial of fluoxetine for adolescents with bulimia nervosa. Journal of Child and Adolescent Psychopharmacology 13: 329–335.
   PubMed Web of Science ®Google Scholar
• Lask B, Fosson A, Rolfe U, Thomas S. 1993. Zinc deficiency and childhood-onset anorexia nervosa. Journal of Clinical Psychiatry 54: 63–66.
   PubMed Web of Science ®Google Scholar
• Lebow J, Sim LA, Erwin PJ, Murad MH. 2013. The effect of atypical antipsychotic medications in individuals with anorexia nervosa: A systematic review and meta-analysis. International Journal of Eating Disorders 46: 332–339.
   PubMed Web of Science ®Google Scholar
• Leggero C, Masi G, Brunori E, Calderoni S, Carissimo R, Maestro S, Muratori F. 2010. Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. Journal of Child and Adolescent Psychopharmacology 20: 127–133.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI. 2007. Atomoxetine in the treatment of binge-eating disorder: a randomised placebo-controlled trial. The Journal of Clinical Psychiatry 68: 390–398.
   PubMed Web of Science ®Google Scholar
• McKnight RF, Park RJ. 2010. Atypical antipsychotics and anorexia nervosa: a review. European Eating Disorders Review 18: 10–21.
   PubMed Web of Science ®Google Scholar
• Mehler-Wex C, Romanos M, Kirchheiner J, Schulze UM. 2008. Atypical antipsychotics in severe anorexia nervosa in children and adolescents—review and case reports. European Eating Disorders Review 16: 100–108.
   PubMed Web of Science ®Google Scholar
• Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann R. 2001. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. European Child & Adolescent Psychiatry 10: 151–157.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, He J, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, Swendsen J. 2010. Lifetime prevalence of mental disorders in US adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry 49: 980–989.
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. 2005. Use of sibutramine an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study. Advances in Therapy 22: 25–31.
   PubMed Web of Science ®Google Scholar
• Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T. 2011. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. Journal of Bone and Mineral Research 26: 2430–2438.
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Roerig J, Steffen K. 2013. Biological therapies for eating disorders. International Journal of Eating Disorders 46: 470–477.
   PubMed Web of Science ®Google Scholar
• Nakash-Eisikovits O, Dierberger A, Westen D. 2002. A multidimensional meta-analysis of pharmacotherapy for bulimia nervosa: summarising the range of outcomes in controlled clinical trials. Harvard Review of Psychiatry 10: 193–211.
   PubMedGoogle Scholar
• Newman-Toker J. 2000. Risperidone in anorexia nervosa. Journal of the American Academy of Child & Adolescent Psychiatry 39: 941–942.
   PubMed Web of Science ®Google Scholar
• NICE (National Institute for Clinical Excellence). 2004a. Eating disorders—core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. NICE Clinical Guideline no 9. Available at http://www.nice.org.uk/nicemedia/live/10932/29218/29218.pdf [accessed 6 January 2014].
   Google Scholar
• NICE (National Institute for Clinical Excellence). 2004b. Quick reference guide: Eating disorders. Available at http://www.nice.org.uk/nicemedia/live/10932/29217/29217.pdf [accessed 6 January 2014].
   Google Scholar
• Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, Lahmann C, Leiberich PK, Krawczyk J, Kettler C. 2005. Topiramate treatment in bulimia nervosa patients: A randomized, double-blind, placebo-controlled trial. International Journal of Eating Disorders 38: 295–300.
   PubMed Web of Science ®Google Scholar
• Norris ML, Spettigue W, Buchholz A, Henderson KA, Gomez R, Maras D, Gaboury I, Ni A. 2011. Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. Journal of Child and Adolescent Psychopharmacology 21: 213–220.
   PubMed Web of Science ®Google Scholar
• Reas DL, Grilo CM. 2008. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity 16: 2024–2038.
   PubMed Web of Science ®Google Scholar
• Reinblatt SP, Redgrave GW, Guarda AS. 2008. Medication management of pediatric eating disorders. International Review of Psychiatry 20: 183–188.
   PubMed Web of Science ®Google Scholar
• Rossi G, Balottin U, Rossi M, Chiappedi M, Fazzi E, Lanzi G. 2007. Pharmacological treatment of anorexia nervosa: a retrospective study in preadolescents and adolescents. Clinical Pediatrics 46: 806–811.
   PubMed Web of Science ®Google Scholar
• Smink FR, van Hoeken D, Hoek HW. 2012. Epidemiology of eating disorders: incidence, prevalence and mortality rates. Current Psychiatry Reports 14: 406–414.
   PubMed Web of Science ®Google Scholar
• Stefano SC, Bacaltchuk J, Blay SL, Appolinário JC. 2008. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eating Behaviors 9: 129–136.
   PubMedGoogle Scholar
• Strike MK, Norris S, Kearney S, Norris ML. 2012. More than just milk: A review of prolactin's impact on the treatment of anorexia nervosa. European Eating Disorders Review 20: e85–e90.
   Google Scholar
• Swanson SA, Crow SJ, Le Grange D, Swendsen J, Merikangas KR. 2011. Prevalence and correlates of eating disorders in adolescents: results from the national comorbidity survey replication adolescent supplement. Archives of General Psychiatry 68: 714–723.
   PubMed Web of Science ®Google Scholar
• Swenne I, Rosling A. 2011. No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders. Journal of Child and Adolescent Psychopharmacology 21: 221–227.
   PubMed Web of Science ®Google Scholar
• van Son GE, van Hoeken D, Bartelds AIM, van Furth EF, Hoek HW. 2006. Time trends in the incidence of eating disorders: A primary care study in The Netherlands. International Journal of Eating Disorders 39: 565–569.
   PubMed Web of Science ®Google Scholar
• Warren MP. 2011. Endocrine manifestations of eating disorders. Journal of Clinical Endocrinology & Metabolism 96: 333–343.
   PubMed Web of Science ®Google Scholar
• Whittal ML, Agras WS, Gould RA. 2000. Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments. Behavior Therapy 30: 117–135.
   Web of Science ®Google Scholar
• Wilfley D, Crow S, Hudson J, Mitchell J, Berkowitz R, Blakesley V, Walsh B. 2008. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. American Journal of Psychiatry 165: 51–58.
   PubMed Web of Science ®Google Scholar
• Wilson GT, Shafran R. 2005. Eating disorders guidelines from NICE. The Lancet 365: 79–81.
   PubMed Web of Science ®Google Scholar
• Yager J, Devlin MJ, Halmi KA, Herzog DB, Mitchell JE, Powers P, Zerbe KJ. 2012. Guideline watch (August 2012): American Psychiatric Association (APA) Practice Guidelines for the treatment of eating disorders (3rd edn). Available at http://psychiatryonline.org/content.aspx?bookid=28&sectionid=39113853 [accessed 6 January 2014].
   Google Scholar